# Geneoscopy > Geneoscopy is a commercial-stage molecular diagnostics company in St. Louis, Missouri, focused on gastrointestinal health. It analyzes stool-derived eukaryotic RNA (seRNA) biomarkers, and its lead product ColoSense is a noninvasive multi-target stool RNA (mt-sRNA) colorectal cancer screening test that the FDA approved in May 2024 for average-risk adults aged 45 and older. Geneoscopy runs a CLIA-certified and CAP-accredited clinical laboratory. It is a diagnostics and laboratory company and publishes no public developer API, SDK, developer portal, or machine-readable API contract. ## Products - [ColoSense](https://www.geneoscopy.com/colosense/): FDA-approved noninvasive multi-target stool RNA colorectal cancer screening test. - [ColoSense patient site](https://colosense.com/): Patient-facing site for ColoSense, including ordering, billing and consent information. - [ColoSense Instructions for Use](https://www.geneoscopy.com/colosense/ifu/): Regulatory Instructions for Use document for the test. - [Colorectal cancer screening](https://www.geneoscopy.com/gastrointestinal-health/colorectal-cancer-screening/) - [Inflammatory bowel disease](https://www.geneoscopy.com/gastrointestinal-health/inflammatory-bowel-disease/) - [Other gastrointestinal diseases](https://www.geneoscopy.com/gastrointestinal-health/other-gastrointestinal-diseases/) - [Gastrointestinal health overview](https://www.geneoscopy.com/gastrointestinal-health/) ## Science and evidence - [Clinical evidence](https://www.geneoscopy.com/gastrointestinal-health/clinical-evidence/) - [Scientific advisory board](https://www.geneoscopy.com/about-us/scientific-advisory-board/) - [Risk information](https://www.geneoscopy.com/risk-information/) ## Company - [About Geneoscopy](https://www.geneoscopy.com/about-us/) - [Our leadership](https://www.geneoscopy.com/about-us/our-leadership/) - [Our lab and our credentials](https://www.geneoscopy.com/about-us/our-lab-and-our-credentials/): CLIA certificate 26D2253457, CAP accreditation, and state laboratory permits. - [Corporate responsibility](https://www.geneoscopy.com/about-us/corporate-responsibility/) - [Partnerships](https://www.geneoscopy.com/partnerships/): BioPharma and research partnerships; inquiries to partnerships@geneoscopy.com. - [Careers](https://www.geneoscopy.com/careers/) - [Contact](https://www.geneoscopy.com/about-us/contact/) ## News - [Newsroom / press releases](https://www.geneoscopy.com/press-releases/) - [Site RSS feed](https://www.geneoscopy.com/feed/) ## Legal - [Terms of Use](https://www.geneoscopy.com/terms-of-use/) - [Privacy Policy](https://www.geneoscopy.com/privacy-policy/) - [HIPAA Notice of Privacy Practices](https://www.geneoscopy.com/notice-of-privacy/) - [SMS terms](https://www.geneoscopy.com/sms/) ## API Evangelist artifacts - [apis.yml](https://raw.githubusercontent.com/api-evangelist/geneoscopy/refs/heads/main/apis.yml): APIs.json 0.20 index for Geneoscopy. - [Domain security](https://raw.githubusercontent.com/api-evangelist/geneoscopy/refs/heads/main/security/geneoscopy-domain-security.yml): Probed TLS/HSTS/DNSSEC/CAA/SPF/DMARC posture for geneoscopy.com and colosense.com. - [Well-known probe record](https://raw.githubusercontent.com/api-evangelist/geneoscopy/refs/heads/main/well-known/geneoscopy-well-known.yml): Result of the /.well-known/ sweep and the full contract-discovery pass (no documents, no spec, no MCP, no agent card). ## Optional - [Geneoscopy stock on Forge Global](https://forgeglobal.com/geneoscopy_stock/): Secondary-market listing for Geneoscopy shares (third party, not operated by Geneoscopy). - [Geneoscopy on LinkedIn](https://www.linkedin.com/company/geneoscopy) - [Geneoscopy on X/Twitter](https://twitter.com/GeneoscopyCo)